Currently, there are 66.28M common shares owned by the public and among those 57.33M shares have been available to trade.
The company’s stock has a 5-day price change of -0.73% and 466.67% over the past three months. RGLS shares are trading 223.81% year to date (YTD), with the 12-month market performance up to 416.46% higher. It has a 12-month low price of $0.83 and touched a high of $8.35 over the same period. RGLS has an average intraday trading volume of 2.52 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.97%, 22.77%, and 195.51% respectively.
Institutional ownership of Regulus Therapeutics Inc (NASDAQ: RGLS) shares accounts for 68.25% of the company’s 66.28M shares outstanding.
It has a market capitalization of $564.95M and a beta (3y monthly) value of 0.37. The earnings-per-share (ttm) stands at -$0.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.02% over the week and 1.45% over the month.
Earnings per share for the fiscal year are expected to decrease by -10.57%, and -16.69% over the next financial year. EPS should shrink at an annualized rate of 11.89% over the next five years, compared to 40.21% over the past 5-year period.
Looking at the support for the RGLS, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on March 27, 2025, with the firm’s price target at $3-$6. Oppenheimer coverage for the Regulus Therapeutics Inc (RGLS) stock in a research note released on August 02, 2024 offered a Outperform rating with a price target of $7. Leerink Partners was of a view on March 18, 2024 that the stock is Outperform, while B. Riley FBR Inc. gave the stock Neutral rating on March 28, 2018, issuing a price target of $1. Leerink Partners on their part issued Outperform rating on January 05, 2018.
